Brooklyn ImmunoTherapeutics is a clinical stage biopharmaceutical company committed to developing IRX-2, a novel hd-IL-2 -based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to potentially restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells.
In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocy...
Brooklyn ImmunoTherapeutics is a clinical stage biopharmaceutical company committed to developing IRX-2, a novel hd-IL-2 -based therapy, to treat patients with cancer. IRX-2 delivers hd-IL-2 and other key cytokines to potentially restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells.
In a Phase 2a clinical trial, IRX-2 demonstrated an increase in tumor infiltrating lymphocytes, which was associated with a survival benefit in patients with head and neck cancer. Based on the encouraging results of the Phase 2a clinical trial, Brooklyn ImmunoTherapeutics initiated a Phase 2b clinical trial.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.